Showing results (361-370 of 413) with videos related to

Sort By:
Pageof 42
European Urology|May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) TrialPrimo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Cancer Causes & Control : CCC|June 14, 2011
Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control studySong Yao, Cathee Till, Alan R Kristal, et al.
Urology|March 4, 2015
Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade diseaseAshraful Hoque, Song Yao, Cathee Till, et al.
Lancet (London, England)|July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trialChristopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
Clinical Chemistry|November 6, 2007
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample biasDale McLerran, William E Grizzle, Ziding Feng, et al.
European Urology Oncology|March 24, 2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or BicalutamideMamta Parikh, Catherine Tangen, Maha H A Hussain, et al.
American Heart Journal|December 6, 2021
Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE studyShalender Bhasin, A Michael Lincoff, Shehzad Basaria, et al.
World Journal of Urology|January 3, 2012
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative GroupDonna P Ankerst, Andreas Boeck, Stephen J Freedland, et al.
Cancer Medicine|April 25, 2022
Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillanceLauren Brady, Lisa F Newcomb, Kehao Zhu, et al.
The New England Journal of Medicine|April 5, 2013
Intermittent versus continuous androgen deprivation in prostate cancerMaha Hussain, Catherine M Tangen, Donna L Berry, et al.
Pageof 42